跳至主要内容
临床试验/NCT05685771
NCT05685771已完成不适用

Assessing the Symptomatic Benefit of Slow-wave Activity Reduction Using Wearables and Sensor-based Characterization of Depression: a Randomized, Counter-balanced Crossover Study

Giulia Da Poian2 个研究点 分布在 1 个国家目标入组 70 人开始时间: 2023年4月1日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
70
试验地点
2
主要终点
Depression severity

研究概览

简要总结

The goal of this clinical trial is to learn about the effects of phase-targeted auditory stimulation in depressed patients and healthy controls.

The main questions it aims to answer are:

  • Is auditory down-phase stimulation efficient in improving depression symptoms as compared to sham stimulation?
  • Can mood and other outcomes be prospectively estimated by multi-parametric passive data?

Participants will perform auditory stimulation using a wearable device at home and provide data on their phone usage and activity.

Researchers will compare depressed patients and healthy participants to see if auditory down-phase stimulation effects them differently.

详细描述

This study consists of two parts:

CLINICAL TRIAL PART: This part will be conducted in depressed and age- and sex-matched healthy participants. It has a double-blind, randomized crossover design. Each participant will undergo 1 week of baseline monitoring, followed by 1 week of in-home stimulation and 1 week of placebo condition interleaved with 1 week wash-out period. The last night of each intervention week will take place in a laboratory setting. A final week of follow-up will follow the second intervention week.

The following data is collected:

  • Single-channel EEG (at home) and high-density electroencephalogram (hdEEG) (in laboratory)
  • MR imaging
  • Daily questionnaires
  • Passive behavioural and physiological measurements

MONITORING PART: This observational study part will be conducted in depressed participants only. Each participant will undergo 5 weeks of remote monitoring using wearable devices and smartphones. Patients not eligible for the CLINICAL TRIAL PART, or that meet an exclusion criterion at any point in the study, can be assigned to this study part.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Crossover
主要目的
Other
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 55 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Male and female adults aged 18-55 years
  • Motivated, no aversion against technology
  • Able to give informed consent as documented by signature, and to follow the technical instructions
  • Able to understand and speak German or English as required for the interview (HDRS) and to answer the questionnaires
  • Diagnosis of depression according to DSM-5 criteria (depressed) OR no diagnosis of depression AND no depressive episode in the history (healthy)
  • ≥17 points in Hamilton Depression Rating Score (HDRS, corresponding to at least moderate-mild depression, depressed) OR <8 points in HDRS (healthy)
  • Stable or no pharmacological antidepressant therapy, no acute suicidal tendency (depressed)

排除标准

  • Pregnant or lactating women, women planning to get pregnant during the study period
  • Bipolar disorder or psychotic symptoms in the history
  • Relevant disease or medication that could present a risk for the participant or that could influence study findings
  • Known sleep apnea (diagnosed or ESS ≥10 points) or periodic limb movement syndrome
  • Known alcoholism or drug abuse
  • Diagnosed hearing impairment/presbycusis
  • Irregular intake of centrally depressing or stimulating medication known to alter sleep EEG (e.g., benzodiazepines)
  • History of traumatic brain injury (except for concussion) or neurosurgical procedures/operations
  • Known epilepsy or for any reason, intracranial space-occupying lesions or (infectious or autoimmune) inflammatory diseases of the central nervous system
  • Shift workers
  • Inability to follow the procedures of the study, e.g., due to language problems, dementia, etc.
  • Skin diseases/skin problems (in the face/ear/chest area) or allergies that could be aggravated by electrode application
  • Conditions that may interfere with the MRI (e.g., MR unsafe cardiac pacemaker or a defibrillator, MR unsafe metal in or near the head, spinal cord, eyes, or in the chest)
  • Indications of sleep apnea (Apnea Hypopnea Index >15/h) or periodic limb movement syndrome (PLMS index >15/h) in the screening night
  • Low stimulation efficiency (<500 stimulations detected by the device) in the screening night or in 3 subsequent home recording nights, e.g., due to very little deep sleep
  • Participation in another clinical trial during the study period

结局指标

主要结局

Depression severity

时间窗: baseline; after first intervention week; after second intervention week

Change in Hamilton Depression Rating Score (HDRS) as compared to baseline score. The 17-item HDRS is on a scale of 0-52 with higher scores indicating more severe symptomatology.

次要结局

  • Subjective momentary sleepiness(first intervention week; second intervention week)
  • Response rate(after first intervention week; after second intervention week)
  • MR Spectroscopy(after first intervention week; after second intervention week)
  • Electroencephalographic (EEG) topography(last night of first intervention week; last night of second intervention week)
  • Brain connectivity(after first intervention week; after second intervention week)

研究者

发起方
Giulia Da Poian
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Giulia Da Poian

Principle Investigator

ETH Zurich

研究点 (2)

Loading locations...

相似试验

Sleep Modulation as Antidepressant Randomized Trial | 临床试验